TY - JOUR
T1 - Valsartan therapy in heart failure after myocardial infarction
T2 - The role of endothelial dependent vasorelaxation
AU - Thai, Hoang
AU - Guarraia, David
AU - Johnson, Nicholle
AU - Goldman, Steven
AU - Gaballa, Mohamed A.
PY - 2007/12
Y1 - 2007/12
N2 - Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.
AB - Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.
KW - Angiotensin II receptors
KW - Conduit arteries
KW - Heart failure
KW - Vasorelaxation
KW - eNOS
UR - http://www.scopus.com/inward/record.url?scp=37348999920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37348999920&partnerID=8YFLogxK
U2 - 10.1097/FJC.0b013e318159378b
DO - 10.1097/FJC.0b013e318159378b
M3 - Article
C2 - 18091589
AN - SCOPUS:37348999920
SN - 0160-2446
VL - 50
SP - 703
EP - 707
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 6
ER -